ADMA Biologics
ADMA · Biotechnology
$10.68
2.5%Cytokinetics
CYTK · Biotechnology
$61.23
1.8%The short version
- ADMA Biologics is the larger business, with $510M of revenue in fiscal 2025 against $88.0M for Cytokinetics, about 5.8 times as much.
- Cytokinetics grew revenue faster (376.6%, against 19.6%).
- ADMA Biologics kept more of each dollar of sales as operating profit (37.5% operating margin, against −695.4% operating margin).
- ADMA Biologics turned more of its sales into free cash flow (5.5% FCF margin, against −607.5% FCF margin).
| Latest fiscal year | ADMA · FY25 | CYTK · FY25 |
|---|---|---|
| Size | ||
| Market cap | $2.5B | — |
| Revenue | $510M | $88.0M |
| Free cash flow | $27.8M | −$535M |
| Net income | $147M | −$785M |
| Growth | ||
| Revenue growth | 19.6% | 376.6% |
| 5-year growth | 64.6% | 9.5% |
| Share count change | 0.6% | — |
| Profitability | ||
| Gross margin | 57.4% | — |
| Operating margin | 37.5% | −695.4% |
| Net margin | 28.8% | −891.6% |
| FCF margin | 5.5% | −607.5% |
| Return on capital | 39.5% | — |
| Return on equity | 35.6% | — |
| Balance sheet | ||
| Net debt | −$15.5M | −$912M |
| Net debt / EBITDA | −0.1x | — |
| Dividends and buybacks | $31.9M | $0.0M |
| Valuation & quality | ||
| P/E | 15.3x | — |
| Piotroski F-score | 5 | — |
FY16
ADMA $10.7M
CYTK $106M
FY17
ADMA $22.8M
CYTK $13.4M
FY18
ADMA $17.0M
CYTK $31.5M
FY19
ADMA $29.3M
CYTK $26.9M
FY20
ADMA $42.2M
CYTK $55.8M
FY21
ADMA $80.9M
CYTK $70.4M
FY22
ADMA $154M
CYTK $94.6M
FY23
ADMA $258M
CYTK $7.5M
FY24
ADMA $427M
CYTK $18.5M
FY25
ADMA $510M
CYTK $88.0M
ADMA
CYTK
FY16
ADMA −162.6%
CYTK 17.6%
FY17
ADMA −172.7%
CYTK −848.3%
FY18
ADMA −355.0%
CYTK −282.3%
FY19
ADMA −141.1%
CYTK −368.0%
FY20
ADMA −153.8%
CYTK −168.3%
FY21
ADMA −72.1%
CYTK −264.5%
FY22
ADMA −25.6%
CYTK −342.8%
FY23
ADMA 8.4%
CYTK −6,589.7%
FY24
ADMA 32.6%
CYTK −2,902.7%
FY25
ADMA 37.5%
CYTK −695.4%
ADMA
CYTK
FY16
ADMA −$18.3M
CYTK $35.4M
FY17
ADMA −$40.0M
CYTK −$105M
FY18
ADMA −$64.8M
CYTK −$102M
FY19
ADMA −$80.0M
CYTK −$93.5M
FY20
ADMA −$115M
CYTK −$2.1M
FY21
ADMA −$126M
CYTK −$191M
FY22
ADMA −$73.4M
CYTK −$311M
FY23
ADMA $4.0M
CYTK −$416M
FY24
ADMA $110M
CYTK −$400M
FY25
ADMA $27.8M
CYTK −$535M
ADMA
CYTK
FY16
ADMA —
CYTK —
FY17
ADMA —
CYTK —
FY18
ADMA —
CYTK —
FY19
ADMA —
CYTK —
FY20
ADMA −82.2%
CYTK —
FY21
ADMA −29.7%
CYTK —
FY22
ADMA −15.8%
CYTK —
FY23
ADMA 8.1%
CYTK —
FY24
ADMA 52.2%
CYTK —
FY25
ADMA 39.5%
CYTK —
ADMA
CYTK
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.